$3.15 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 90 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AHCO | ADAPTHEALTH CORP | $275,198,000 | +45.7% | 17,199,888 | 0.0% | 8.73% | +44.9% | |
| HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $168,706,000 | -11.9% | 144,832,000 | 0.0% | 5.35% | -12.4% | ||
| NEVRO CORPnote 1.750% 6/0 | $133,920,000 | -13.2% | 115,776,000 | 0.0% | 4.25% | -13.6% | ||
| ORTX | ORCHARD THERAPEUTICS PLCads | $66,733,000 | -45.2% | 8,862,247 | 0.0% | 2.12% | -45.5% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $48,285,000 | -42.9% | 3,448,912 | 0.0% | 1.53% | -43.2% | |
| INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $46,815,000 | -19.6% | 57,791,000 | 0.0% | 1.49% | -20.1% | ||
| CLOVIS ONCOLOGY INCnote 2.500% 9/1 | $43,581,000 | +1.6% | 49,064,000 | 0.0% | 1.38% | +1.0% | ||
| PTC THERAPEUTICS INCnote 3.000% 8/1 | $26,850,000 | -5.5% | 24,877,000 | 0.0% | 0.85% | -6.0% | ||
| EDIT | EDITAS MEDICINE INC | $22,980,000 | -33.0% | 1,158,841 | 0.0% | 0.73% | -33.4% | |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $21,283,000 | -29.8% | 788,243 | 0.0% | 0.68% | -30.3% | |
| SIEN | SIENTRA INC | $8,413,000 | -77.7% | 4,227,680 | 0.0% | 0.27% | -77.9% | |
| MNKKQ | MALLINCKRODT PUB LTD CO | $7,973,000 | -43.3% | 4,026,750 | 0.0% | 0.25% | -43.5% | |
| SYRS | SYROS PHARMACEUTICALS INC | $7,525,000 | -14.2% | 1,268,946 | 0.0% | 0.24% | -14.6% | |
| NEOS | NEOS THERAPEUTICS INC | $241,000 | -50.3% | 320,993 | 0.0% | 0.01% | -46.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.